Loblaw Companies (TSE:L – Get Free Report) has been assigned a C$225.00 price objective by analysts at UBS Group in a note issued to investors on Friday,BayStreet.CA reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s target price suggests a potential upside of 16.00% from the stock’s current price.
Other equities analysts have also issued research reports about the stock. TD Securities cut their price target on shares of Loblaw Companies from C$203.00 to C$202.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Royal Bank of Canada upped their price target on Loblaw Companies from C$205.00 to C$217.00 and gave the company an “outperform” rating in a research report on Monday, December 9th. Desjardins raised their price objective on Loblaw Companies from C$172.00 to C$190.00 in a research report on Thursday, November 14th. National Bankshares upped their target price on Loblaw Companies from C$188.00 to C$195.00 in a report on Thursday, November 14th. Finally, CIBC increased their target price on shares of Loblaw Companies from C$189.00 to C$206.00 in a research report on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of C$197.00.
Get Our Latest Research Report on L
Loblaw Companies Stock Down 0.2 %
About Loblaw Companies
Loblaw is one of Canada’s largest grocery, pharmacy, and general merchandise retailers, operating the most expansive store footprint in Ontario and maintaining sizable presences in provinces like Quebec and British Columbia. Key grocery banners include Loblaw, No Frills, and Maxi, while its pharmaceutical operations are the product of its 2014 acquisition of Shoppers Drug Mart.
See Also
- Five stocks we like better than Loblaw Companies
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Using the MarketBeat Dividend Tax Calculator
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Loblaw Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loblaw Companies and related companies with MarketBeat.com's FREE daily email newsletter.